Muhammad Khurram Nisar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Muhammad Khurram Nisar has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
Andrew J. K. Östör
Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, UK
7 shared publicationsJulie Begum
Department of Rheumatology, Luton & Dunstable University Hospital NHSFT, Luton, UK
5 shared publicationsAhmed Fahim
Department of Respiratory Medicine, Royal Wolverhampton NHS Trust , Wolverhampton
2 shared publicationsAli K. Abbas
Luton & Dunstable University Hospital, Luton, UK
2 shared publicationsAndreas V. Hadjinicolaou
Rheumatology Research Unit, Box 194. Addenbrooke's Hospital, CUHNHSFT, Cambridge CB2 2QQ, UK
2 shared publicationsAneesa Rafiq
Rheumatology Department, Luton & Dunstable University Hospital NHSFT, Luton, UK
2 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (11)
The 2026 BSR Guideline for the diagnosis and management of systemic autoimmune rheumatic disease associated interstitial lung disease (SARD-ILD)
- 1 November 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (11)
Open AccessThe 2026 BSR Guideline for the diagnosis and management of systemic autoimmune rheumatic disease associated interstitial lung disease (SARD-ILD)
- 19 June 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (7) , 4277-4285
The effect of biologic disease modifying anti-rheumatic drugs on the neutrophil–lymphocyte ratio in psoriatic arthritis patients
Cardiovascular mortality is up to 43% greater in patients with Psoriatic Arthritis (PsA) when compared to the general population. Whilst composite cardiovascular disease risk prognosticators exist, an emerging inexpensive biomarker known as the neutrophil-lymphocyte ratio (NLR) has been demonstrated to be a risk-associated biomarker of cardiovascular disease (CVD) in the general population. This study therefore aimed to assess the effect of biologic disease modifying antirheumatic drug (bDMARDs) on the NLR in a cohort of adult patients diagnosed with PsA. A retrospective single-centre observational study was conducted using an electronic health record database including 183 adult patients diagnosed with PsA between 1983 and 2024. The NLR of patients was calculated pre- and post-initiation of bDMARDs and statistical significance was analysed using several different statistical analysis tools. The overall number of patients in the higher NLR risk stratification group (NLR > 2) was significantly reduced from 104 to 64 post-biologic initiation. Additionally, there was a statistically significant reduction of 24.0% in the average NLR of the entire patient cohort from 2.58 to 1.96 pre- and post-biologic initiation respectively. Our study demonstrates that over a third of patients had a significant NLR reduction post-biologic initiation. The mean NLR of the entire patient cohort demonstrated a shift to a lower CVD risk-associated stratified NLR group (NLR < 2), post-biologic treatment. BDMARD treatment in PsA patients therefore demonstrates a significant reduction in the NLR metric, with a varying degree of theoretical impact on the CVD risk reduction among different biologic drugs and classes. Key Points • bDMARDs reduce the Neutrophil-Lymphocyte Ratio in Psoriatic Arthritis patients. • Both TNF inhibitor and IL-17 inhibitors bDMARDs were associated with significant reductions in the Neutrophil-Lymphocyte Ratio in Psoriatic Arthritis patients.
- 19 June 2026
- Published by Springer Nature in Clinical Rheumatology
- Vol. 45 (7) , 4277-4285
The effect of biologic disease modifying anti-rheumatic drugs on the neutrophil–lymphocyte ratio in psoriatic arthritis patients
Cardiovascular mortality is up to 43% greater in patients with Psoriatic Arthritis (PsA) when compared to the general population. Whilst composite cardiovascular disease risk prognosticators exist, an emerging inexpensive biomarker known as the neutrophil-lymphocyte ratio (NLR) has been demonstrated to be a risk-associated biomarker of cardiovascular disease (CVD) in the general population. This study therefore aimed to assess the effect of biologic disease modifying antirheumatic drug (bDMARDs) on the NLR in a cohort of adult patients diagnosed with PsA. A retrospective single-centre observational study was conducted using an electronic health record database including 183 adult patients diagnosed with PsA between 1983 and 2024. The NLR of patients was calculated pre- and post-initiation of bDMARDs and statistical significance was analysed using several different statistical analysis tools. The overall number of patients in the higher NLR risk stratification group (NLR > 2) was significantly reduced from 104 to 64 post-biologic initiation. Additionally, there was a statistically significant reduction of 24.0% in the average NLR of the entire patient cohort from 2.58 to 1.96 pre- and post-biologic initiation respectively. Our study demonstrates that over a third of patients had a significant NLR reduction post-biologic initiation. The mean NLR of the entire patient cohort demonstrated a shift to a lower CVD risk-associated stratified NLR group (NLR < 2), post-biologic treatment. BDMARD treatment in PsA patients therefore demonstrates a significant reduction in the NLR metric, with a varying degree of theoretical impact on the CVD risk reduction among different biologic drugs and classes. Key Points • bDMARDs reduce the Neutrophil-Lymphocyte Ratio in Psoriatic Arthritis patients. • Both TNF inhibitor and IL-17 inhibitors bDMARDs were associated with significant reductions in the Neutrophil-Lymphocyte Ratio in Psoriatic Arthritis patients.
- 5 December 2025
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (2) , 633-649
Cost-Utility Analysis of Subcutaneous Methotrexate in the Treatment of Patients with Rheumatoid Arthritis in the UK
Introduction Oral methotrexate is the standard first-line treatment for rheumatoid arthritis (RA), but subcutaneous methotrexate may offer improved efficacy and tolerability and, as a second-line treatment, delay escalation to biologics. This study evaluates the cost-utility of treatment pathways including subcutaneous methotrexate versus current practice for moderate-to-severe RA in the UK. Methods A hybrid decision tree-Markov model simulating RA treatment pathways was developed. The decision tree classified patients as (non-)responders based on American College of Rheumatology criteria. Responders continued first-line therapy; non-responders transitioned to second-line treatment. In the Markov model, states were defined by treatment line, with patient entry determined by decision tree outcomes. Transitions represented discontinuation due to inefficacy or toxicity. Health Assessment Questionnaire scores changed over time by Markov state, affecting quality of life, mortality, and hospitalisation costs. Resource use, adverse events, and treatment costs were included. Inputs were sourced from peer-reviewed literature, national costing databases, and health technology appraisals. Results Over 30 years, the pathway including second-line subcutaneous methotrexate was projected as less costly and more effective than current practice with £5217 in total cost savings and 0.23 quality-adjusted life years gained per patient, for a net monetary benefit of £9789. One-way and probabilistic sensitivity and scenario analyses supported the robustness of results. Dominance was maintained across all variations and iterations, including a scenario with first-line subcutaneous methotrexate. Conclusion Including subcutaneous methotrexate as second-line RA treatment after oral methotrexate represents effective healthcare resource use in the UK, improving patient outcomes while reducing total costs.
- 5 December 2025
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (2) , 633-649
Cost-Utility Analysis of Subcutaneous Methotrexate in the Treatment of Patients with Rheumatoid Arthritis in the UK
Introduction Oral methotrexate is the standard first-line treatment for rheumatoid arthritis (RA), but subcutaneous methotrexate may offer improved efficacy and tolerability and, as a second-line treatment, delay escalation to biologics. This study evaluates the cost-utility of treatment pathways including subcutaneous methotrexate versus current practice for moderate-to-severe RA in the UK. Methods A hybrid decision tree-Markov model simulating RA treatment pathways was developed. The decision tree classified patients as (non-)responders based on American College of Rheumatology criteria. Responders continued first-line therapy; non-responders transitioned to second-line treatment. In the Markov model, states were defined by treatment line, with patient entry determined by decision tree outcomes. Transitions represented discontinuation due to inefficacy or toxicity. Health Assessment Questionnaire scores changed over time by Markov state, affecting quality of life, mortality, and hospitalisation costs. Resource use, adverse events, and treatment costs were included. Inputs were sourced from peer-reviewed literature, national costing databases, and health technology appraisals. Results Over 30 years, the pathway including second-line subcutaneous methotrexate was projected as less costly and more effective than current practice with £5217 in total cost savings and 0.23 quality-adjusted life years gained per patient, for a net monetary benefit of £9789. One-way and probabilistic sensitivity and scenario analyses supported the robustness of results. Dominance was maintained across all variations and iterations, including a scenario with first-line subcutaneous methotrexate. Conclusion Including subcutaneous methotrexate as second-line RA treatment after oral methotrexate represents effective healthcare resource use in the UK, improving patient outcomes while reducing total costs.
- Open Access
- 9 April 2025
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 96 (1)
Rheumatic conditions associated with interstitial lung diseases: real-world outcomes in a secondary care setting
Management of rheumatic conditions associated with interstitial lung disease (r-ILD) requires expertise, often occurring in tertiary referral centers. We set up a combined rheumatology and respiratory service in a district general hospital (DGH) to avoid long patient journeys and improve experience. We evaluated the outcomes of 104 patients managed in this pilot service model. Referrals were triaged in monthly ILD multidisciplinary team meetings, and appropriate patients were booked into the clinic. All data were recorded electronically with full access to demographics, disease parameters, investigations, and drug management. Of the patients who attended follow-up, 51 (51%) had stable or improved symptoms, 58 (67%) had stable or improved computed tomography imaging, 50 (78%) had stable or improved forced vital capacity, and 40 (77%) had stable or improved diffusing capacity of the lungs for carbon monoxide. There were similar improvements in 6-minute walk tests. A total of 27 patients died, with 33% of these deemed a direct result of their ILD. Our report confirms that r-ILD can be successfully managed in a DGH setting, with a large cohort obtaining good, comparable clinical outcomes. We show that r-ILD services can be established locally to help overstretched tertiary care while developing local expertise in the management of r-ILD.
- 9 April 2025
- Published by PAGEPress Publications in Monaldi Archives for Chest Disease
- Vol. 96 (1)
Open AccessRheumatic conditions associated with interstitial lung diseases: real-world outcomes in a secondary care setting
Management of rheumatic conditions associated with interstitial lung disease (r-ILD) requires expertise, often occurring in tertiary referral centers. We set up a combined rheumatology and respiratory service in a district general hospital (DGH) to avoid long patient journeys and improve experience. We evaluated the outcomes of 104 patients managed in this pilot service model. Referrals were triaged in monthly ILD multidisciplinary team meetings, and appropriate patients were booked into the clinic. All data were recorded electronically with full access to demographics, disease parameters, investigations, and drug management. Of the patients who attended follow-up, 51 (51%) had stable or improved symptoms, 58 (67%) had stable or improved computed tomography imaging, 50 (78%) had stable or improved forced vital capacity, and 40 (77%) had stable or improved diffusing capacity of the lungs for carbon monoxide. There were similar improvements in 6-minute walk tests. A total of 27 patients died, with 33% of these deemed a direct result of their ILD. Our report confirms that r-ILD can be successfully managed in a DGH setting, with a large cohort obtaining good, comparable clinical outcomes. We show that r-ILD services can be established locally to help overstretched tertiary care while developing local expertise in the management of r-ILD.
- Open Access
- 1 May 2024
- Published by Springer Nature in BJC Reports
- Vol. 2 (1) , 1-5
Aromatase inhibitors and fracture prevention – do 2017 guidelines work in real world?
Objectives: Aromatase inhibitor induced bone loss (AIBL) is a recognised adverse event with resultant increase in fracture risk. We aimed to determine the real-world impact of the 2017 consensus guidelines on AIBL and see if it is effective in fracture prevention. Methods: Over a 7-year study period, 1001 women prescribed AI were split in two groups. First group were offered bone active treatment based on NOS 2008 guidelines whereas the second group followed the 2017 consensus guidelines. Results: 1001 women were included. First group: 361 women had a baseline DEXA with 143 (40%) women who had a normal DEXA, 174 (48%) had osteopenia and 44 (12%) had osteoporosis. Of the women with osteopenia, 44 (25%) women were offered treatment, and 22 (13%) women had a fracture. Second group: 640 women had a baseline DEXA with 216 (33%) women with a normal result, 322(50%) had osteopenia and 107 (17%) had osteoporosis. Of the women with osteopenia, 127 (39%) women were offered treatment, and 8 (2.5%) women had a fracture. Conclusions: Our study provides real world evidence of the success of 2017 consensus statement in lowering fracture risk. A significant reduction in fractures pre (13%) and post guidelines change (2.5%) was demonstrated (absolute risk reduction of 10.5%) which has implications for healthcare systems worldwide as we have demonstrated this approach can reduce morbidity. Lay summary: Breast cancer is the most common cancer in women with over two million women diagnosed with it annually. Early diagnosis and treatment with hormonal therapies have helped reduce mortality. Aromatase inhibitors (AIs) are the main drugs in this class and have demonstrated improved survival. However, whilst conveying major benefits, AIs reduce oestrogen levels leading to significant bone loss and increasing fracture risk. Several protocols have been recommended to address this concern. We compared the two guidelines published by National Osteoporosis Society UK in 2008 and consensus statement recommended by seven breast cancer and bone health groups in 2017 to see which work better in preventing fractures in women prescribed AIs for breast cancer. Our study shows that the 2017 guidelines are better at preventing fractures in the real world. Hence, we suggest that these should be adopted by specialists treating breast cancer which can help women avoid fractures and improve long term health.
- 1 May 2024
- Published by Springer Nature in BJC Reports
- Vol. 2 (1) , 1-5
Open AccessAromatase inhibitors and fracture prevention – do 2017 guidelines work in real world?
Objectives: Aromatase inhibitor induced bone loss (AIBL) is a recognised adverse event with resultant increase in fracture risk. We aimed to determine the real-world impact of the 2017 consensus guidelines on AIBL and see if it is effective in fracture prevention. Methods: Over a 7-year study period, 1001 women prescribed AI were split in two groups. First group were offered bone active treatment based on NOS 2008 guidelines whereas the second group followed the 2017 consensus guidelines. Results: 1001 women were included. First group: 361 women had a baseline DEXA with 143 (40%) women who had a normal DEXA, 174 (48%) had osteopenia and 44 (12%) had osteoporosis. Of the women with osteopenia, 44 (25%) women were offered treatment, and 22 (13%) women had a fracture. Second group: 640 women had a baseline DEXA with 216 (33%) women with a normal result, 322(50%) had osteopenia and 107 (17%) had osteoporosis. Of the women with osteopenia, 127 (39%) women were offered treatment, and 8 (2.5%) women had a fracture. Conclusions: Our study provides real world evidence of the success of 2017 consensus statement in lowering fracture risk. A significant reduction in fractures pre (13%) and post guidelines change (2.5%) was demonstrated (absolute risk reduction of 10.5%) which has implications for healthcare systems worldwide as we have demonstrated this approach can reduce morbidity. Lay summary: Breast cancer is the most common cancer in women with over two million women diagnosed with it annually. Early diagnosis and treatment with hormonal therapies have helped reduce mortality. Aromatase inhibitors (AIs) are the main drugs in this class and have demonstrated improved survival. However, whilst conveying major benefits, AIs reduce oestrogen levels leading to significant bone loss and increasing fracture risk. Several protocols have been recommended to address this concern. We compared the two guidelines published by National Osteoporosis Society UK in 2008 and consensus statement recommended by seven breast cancer and bone health groups in 2017 to see which work better in preventing fractures in women prescribed AIs for breast cancer. Our study shows that the 2017 guidelines are better at preventing fractures in the real world. Hence, we suggest that these should be adopted by specialists treating breast cancer which can help women avoid fractures and improve long term health.
- Open Access
- 14 March 2024
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 8 (2) , rkae056
The diagnosis and management of systemic autoimmune rheumatic disease-related interstitial lung disease: British Society for Rheumatology guideline scope
Interstitial lung disease (ILD) is a significant complication of many systemic autoimmune rheumatic diseases (SARDs), although the clinical presentation, severity and outlook may vary widely between individuals. Despite the prevalence, there are no specific guidelines addressing the issue of screening, diagnosis and management of ILD across this diverse group. Guidelines from the ACR and EULAR are expected, but there is a need for UK-specific guidelines that consider the framework of the UK National Health Service, local licensing and funding strategies. This article outlines the intended scope for the British Society for Rheumatology guideline on the diagnosis and management of SARD-ILD developed by the guideline working group. It specifically identifies the SARDs for consideration, alongside the overarching principles for which systematic review will be conducted. Expert consensus will be produced based on the most up-to-date available evidence for inclusion within the final guideline. Key issues to be addressed include recommendations for screening of ILD, identifying the methodology and frequency of monitoring and pharmacological and non-pharmacological management. The guideline will be developed according to methods and processes outlined in Creating Clinical Guidelines: British Society for Rheumatology Protocol version 5.1.
- 14 March 2024
- Published by Oxford University Press (OUP) in Rheumatology Advances in Practice
- Vol. 8 (2) , rkae056
Open AccessThe diagnosis and management of systemic autoimmune rheumatic disease-related interstitial lung disease: British Society for Rheumatology guideline scope
Interstitial lung disease (ILD) is a significant complication of many systemic autoimmune rheumatic diseases (SARDs), although the clinical presentation, severity and outlook may vary widely between individuals. Despite the prevalence, there are no specific guidelines addressing the issue of screening, diagnosis and management of ILD across this diverse group. Guidelines from the ACR and EULAR are expected, but there is a need for UK-specific guidelines that consider the framework of the UK National Health Service, local licensing and funding strategies. This article outlines the intended scope for the British Society for Rheumatology guideline on the diagnosis and management of SARD-ILD developed by the guideline working group. It specifically identifies the SARDs for consideration, alongside the overarching principles for which systematic review will be conducted. Expert consensus will be produced based on the most up-to-date available evidence for inclusion within the final guideline. Key issues to be addressed include recommendations for screening of ILD, identifying the methodology and frequency of monitoring and pharmacological and non-pharmacological management. The guideline will be developed according to methods and processes outlined in Creating Clinical Guidelines: British Society for Rheumatology Protocol version 5.1.
- Open Access
- 28 June 2023
- Published by Springer Nature in Research Square
Aromatase inhibitors and fracture prevention – do 2017 guidelines work in real world?
Objectives: Aromatase inhibitor induced bone loss (AIBL) is a recognised adverse event with resultant increase in fracture risk. We aimed to determine the real-world impact of the 2017 consensus guidelines on AIBL and it is effective in fracture prevention. Methods: Over a 7-year study period, 1001 women prescribed AI were split in two groups. First group were offered bone active treatment based on NOS 2009 guidelines whereas the second group followed the 2017 consensus guidelines. Results: 1001 women were included. First group: 361 women had a baseline DEXA with 143 (40%) women had a normal DEXA, 174 (48%) had osteopenia and 44 (12%) had osteoporosis. Of the women with osteopenia, 44 (25%) women were offered treatment and 22 (13%) women had a fracture. Second group: 640 women had a baseline DEXA with 216 (33%) women were normal, 322(50%) had osteopenia and 107 (17%) had osteoporosis. Of the women with osteopenia, 127 (39%) women were offered treatment and 8 (2.5%) women had a fracture. Conclusions: Our study provides real world evidence of the success of 2017 consensus statement in lowering fracture risk. A significant reduction in fractures pre (13%) and post guidelines change (2.5%) was demonstrated (absolute risk reduction of 10.5%) which has implications for healthcare systems worldwide as we have demonstrated this approach can reduce morbidity.
- 28 June 2023
- Published by Springer Nature in Research Square
Open AccessAromatase inhibitors and fracture prevention – do 2017 guidelines work in real world?
Objectives: Aromatase inhibitor induced bone loss (AIBL) is a recognised adverse event with resultant increase in fracture risk. We aimed to determine the real-world impact of the 2017 consensus guidelines on AIBL and it is effective in fracture prevention. Methods: Over a 7-year study period, 1001 women prescribed AI were split in two groups. First group were offered bone active treatment based on NOS 2009 guidelines whereas the second group followed the 2017 consensus guidelines. Results: 1001 women were included. First group: 361 women had a baseline DEXA with 143 (40%) women had a normal DEXA, 174 (48%) had osteopenia and 44 (12%) had osteoporosis. Of the women with osteopenia, 44 (25%) women were offered treatment and 22 (13%) women had a fracture. Second group: 640 women had a baseline DEXA with 216 (33%) women were normal, 322(50%) had osteopenia and 107 (17%) had osteoporosis. Of the women with osteopenia, 127 (39%) women were offered treatment and 8 (2.5%) women had a fracture. Conclusions: Our study provides real world evidence of the success of 2017 consensus statement in lowering fracture risk. A significant reduction in fractures pre (13%) and post guidelines change (2.5%) was demonstrated (absolute risk reduction of 10.5%) which has implications for healthcare systems worldwide as we have demonstrated this approach can reduce morbidity.
- Open Access
- 14 February 2023
- Published by Springer Nature in BMC Medicine
- Vol. 21 (1) , 1-10
Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease
Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease that is associated with joint pain and stiffness. Biologics represent some of the most effective treatments for RA, but previous guidance from the National Institute for Health and Care Excellence (NICE) has limited their use to patients with severely active disease. This has meant patients with moderately active RA have been treated as if they have an acceptable disease state, despite many cases where the inflammation has a major impact on joint damage, mobility, pain and quality of life. However, recent guideline changes (NICE TA715) have approved the use of three biologics — adalimumab, etanercept and infliximab — for the treatment of moderately active RA. Main body: In response to these changes, we have held discussions with medical teams from across the UK to consider the main implications for implementation of these new recommendations, as well as any differences in approach that may exist at a local level. Several key challenges were identified. These included establishing methods of educating both physicians and patients concerning the new availability of the biologic treatments, with suggestions of various organisations that could be approached to circulate informative material. Identifying which patients with moderately active RA stand to benefit was another discussion topic. Relying solely on scoring systems like Disease Activity Score in 28 Joints (DAS28) was acknowledged to have limitations, and alternative complementary approaches such as ultrasound, as well as assessing a patient’s co-morbidities, could also be useful tools in determining those who could benefit from biologics. An additional challenge for the process of patient identification has been the increase in the use of telemedicine consultations in response to the coronavirus disease 2019 (COVID-19) pandemic. More use of patient-reported outcomes was raised as one possible solution, and the importance of maintaining up-to-date databases on patient disease scores and treatment history was also stressed. Conclusion: While challenges exist in education and identifying patients who may benefit from the use of biologics, the NICE TA715 recommendations hold great potential in addressing an unmet need for the treatment of moderate RA.
- 14 February 2023
- Published by Springer Nature in BMC Medicine
- Vol. 21 (1) , 1-10
Open AccessApproaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease
Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease that is associated with joint pain and stiffness. Biologics represent some of the most effective treatments for RA, but previous guidance from the National Institute for Health and Care Excellence (NICE) has limited their use to patients with severely active disease. This has meant patients with moderately active RA have been treated as if they have an acceptable disease state, despite many cases where the inflammation has a major impact on joint damage, mobility, pain and quality of life. However, recent guideline changes (NICE TA715) have approved the use of three biologics — adalimumab, etanercept and infliximab — for the treatment of moderately active RA. Main body: In response to these changes, we have held discussions with medical teams from across the UK to consider the main implications for implementation of these new recommendations, as well as any differences in approach that may exist at a local level. Several key challenges were identified. These included establishing methods of educating both physicians and patients concerning the new availability of the biologic treatments, with suggestions of various organisations that could be approached to circulate informative material. Identifying which patients with moderately active RA stand to benefit was another discussion topic. Relying solely on scoring systems like Disease Activity Score in 28 Joints (DAS28) was acknowledged to have limitations, and alternative complementary approaches such as ultrasound, as well as assessing a patient’s co-morbidities, could also be useful tools in determining those who could benefit from biologics. An additional challenge for the process of patient identification has been the increase in the use of telemedicine consultations in response to the coronavirus disease 2019 (COVID-19) pandemic. More use of patient-reported outcomes was raised as one possible solution, and the importance of maintaining up-to-date databases on patient disease scores and treatment history was also stressed. Conclusion: While challenges exist in education and identifying patients who may benefit from the use of biologics, the NICE TA715 recommendations hold great potential in addressing an unmet need for the treatment of moderate RA.
- Open Access
- 24 January 2022
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 9 (2) , 100-103
How well are biologic and conventional DMARDs tolerated in psoriatic arthritis: A real world study
Objective: Even though disease-modifying antirheumatic drugs (DMARDs) are well established in rou- tine clinical practice, longitudinal real-world data for their retention and tolerability are sparse, espe- cially in psoriatic arthritis (PsA) patients. Our objective was to describe the characteristics of our large PsA cohort including the comorbidities and evaluate real-world DMARD tolerability and discontinua- tion rates with reasons for stopping treatment. Methods: We retrospectively interrogated the electronic, multipurpose, live setting database at our uni- versity hospital to identify 335 patients diagnosed with PsA who had received conventional DMARDs (cDMARDs) and/or biologic DMARDs (bDMARDs) between 1994 up to and including April 2019. Results: In total, 170 (50.7%) patients had discontinued one or more cDMARDs prior with a mean dura- tion before discontinuation of 9.9 months. In contrast, only 28 (24.8%) patients had stopped a course of bDMARDs at some point. The mean duration before biologic therapy was discontinued was 18.2 months. Conclusion: To our knowledge, this is the first dedicated retrospective review of a large real-world PsA cohort addressing drug survival and tolerability of DMARDs over a 20-year period. Our study shows that in reality, cDMARDs are not well tolerated. This should encourage review of international guid- ance allowing earlier employment of biologics in the treatment paradigm. Cite this article as: Jawad II, Nisar MK. How well are biologic and conventional DMARDs tolerated in psoriatic arthritis: A real world study. Eur J Rheumatol.2022;9(2):100-103.
- 24 January 2022
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 9 (2) , 100-103
Open AccessHow well are biologic and conventional DMARDs tolerated in psoriatic arthritis: A real world study
Objective: Even though disease-modifying antirheumatic drugs (DMARDs) are well established in rou- tine clinical practice, longitudinal real-world data for their retention and tolerability are sparse, espe- cially in psoriatic arthritis (PsA) patients. Our objective was to describe the characteristics of our large PsA cohort including the comorbidities and evaluate real-world DMARD tolerability and discontinua- tion rates with reasons for stopping treatment. Methods: We retrospectively interrogated the electronic, multipurpose, live setting database at our uni- versity hospital to identify 335 patients diagnosed with PsA who had received conventional DMARDs (cDMARDs) and/or biologic DMARDs (bDMARDs) between 1994 up to and including April 2019. Results: In total, 170 (50.7%) patients had discontinued one or more cDMARDs prior with a mean dura- tion before discontinuation of 9.9 months. In contrast, only 28 (24.8%) patients had stopped a course of bDMARDs at some point. The mean duration before biologic therapy was discontinued was 18.2 months. Conclusion: To our knowledge, this is the first dedicated retrospective review of a large real-world PsA cohort addressing drug survival and tolerability of DMARDs over a 20-year period. Our study shows that in reality, cDMARDs are not well tolerated. This should encourage review of international guid- ance allowing earlier employment of biologics in the treatment paradigm. Cite this article as: Jawad II, Nisar MK. How well are biologic and conventional DMARDs tolerated in psoriatic arthritis: A real world study. Eur J Rheumatol.2022;9(2):100-103.
- Open Access
- 14 December 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (24) , 5863
Biomarkers Predict In-Hospital Major Adverse Cardiac Events in COVID-19 Patients: A Multicenter International Study
Background: The COVID-19 pandemic carries a high burden of morbidity and mortality worldwide. We aimed to identify possible predictors of in-hospital major cardiovascular (CV) events in COVID-19. Methods: We retrospectively included patients hospitalized for COVID-19 from 10 centers. Clinical, biochemical, electrocardiographic, and imaging data at admission and medications were collected. Primary endpoint was a composite of in-hospital CV death, acute heart failure (AHF), acute myocarditis, arrhythmias, acute coronary syndromes (ACS), cardiocirculatory arrest, and pulmonary embolism (PE). Results: Of the 748 patients included, 141(19%) reached the set endpoint: 49 (7%) CV death, 15 (2%) acute myocarditis, 32 (4%) sustained-supraventricular or ventricular arrhythmias, 14 (2%) cardiocirculatory arrest, 8 (1%) ACS, 41 (5%) AHF, and 39 (5%) PE. Patients with CV events had higher age, body temperature, creatinine, high-sensitivity troponin, white blood cells, and platelet counts at admission and were more likely to have systemic hypertension, renal failure (creatinine ≥ 1.25 mg/dL), chronic obstructive pulmonary disease, atrial fibrillation, and cardiomyopathy. On univariate and multivariate analysis, troponin and renal failure were associated with the composite endpoint. Kaplan–Meier analysis showed a clear divergence of in-hospital composite event-free survival stratified according to median troponin value and the presence of renal failure (Log rank p < 0.001). Conclusions: Our findings, derived from a multicenter data collection study, suggest the routine use of biomarkers, such as cardiac troponin and serum creatinine, for in-hospital prediction of CV events in patients with COVID-19.
- 14 December 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (24) , 5863
Open AccessBiomarkers Predict In-Hospital Major Adverse Cardiac Events in COVID-19 Patients: A Multicenter International Study
Background: The COVID-19 pandemic carries a high burden of morbidity and mortality worldwide. We aimed to identify possible predictors of in-hospital major cardiovascular (CV) events in COVID-19. Methods: We retrospectively included patients hospitalized for COVID-19 from 10 centers. Clinical, biochemical, electrocardiographic, and imaging data at admission and medications were collected. Primary endpoint was a composite of in-hospital CV death, acute heart failure (AHF), acute myocarditis, arrhythmias, acute coronary syndromes (ACS), cardiocirculatory arrest, and pulmonary embolism (PE). Results: Of the 748 patients included, 141(19%) reached the set endpoint: 49 (7%) CV death, 15 (2%) acute myocarditis, 32 (4%) sustained-supraventricular or ventricular arrhythmias, 14 (2%) cardiocirculatory arrest, 8 (1%) ACS, 41 (5%) AHF, and 39 (5%) PE. Patients with CV events had higher age, body temperature, creatinine, high-sensitivity troponin, white blood cells, and platelet counts at admission and were more likely to have systemic hypertension, renal failure (creatinine ≥ 1.25 mg/dL), chronic obstructive pulmonary disease, atrial fibrillation, and cardiomyopathy. On univariate and multivariate analysis, troponin and renal failure were associated with the composite endpoint. Kaplan–Meier analysis showed a clear divergence of in-hospital composite event-free survival stratified according to median troponin value and the presence of renal failure (Log rank p < 0.001). Conclusions: Our findings, derived from a multicenter data collection study, suggest the routine use of biomarkers, such as cardiac troponin and serum creatinine, for in-hospital prediction of CV events in patients with COVID-19.